<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533243</url>
  </required_header>
  <id_info>
    <org_study_id>SYLT-19</org_study_id>
    <nct_id>NCT04533243</nct_id>
  </id_info>
  <brief_title>Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain</brief_title>
  <official_title>Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain: A Prospective, Randomized, Controlled, Multi-center, Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Opioid is recommended for moderate cancer pain in WHO 3-step analgesic ladder. Transdermal&#xD;
      administration of the strong opioid fentanyl was originally developed for patients unable to&#xD;
      swallow analgesics because of malignancies in the head and neck region or the&#xD;
      gastrointestinal tract, painful lesions in the mouth, or periods of nausea, vomiting, or&#xD;
      bowel obstruction. The EMA recognizes that in exceptional clinical circumstances, the 12 μg/h&#xD;
      fentanyl patch could be considered. To our knowledge, there is not a phase III trial to&#xD;
      explore the efficacy and safety of 12 μg/h fentanyl patch in opioid-naive patients with&#xD;
      moderate cancer pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the number of responder patients</measure>
    <time_frame>12 months</time_frame>
    <description>the number of responder patients is defined as patientswith a 20% reduction in pain intensity on the numerical rating scale.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">209</enrollment>
  <condition>Opioid, Moderate Cancer Pain, Transdermal Fentanyl, 12.5ug/h, Opioid-naive</condition>
  <arm_group>
    <arm_group_label>2.5ug/h transdermal fentanyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral immediate-released morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2.5ug/h transdermal fentanyl</intervention_name>
    <description>2.5ug/h transdermal fentanyl administers for opioid-naive patients with moderate cancer pain very 3 days</description>
    <arm_group_label>2.5ug/h transdermal fentanyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral immediate-released morphine</intervention_name>
    <description>5mg immediate-released morphine every 4 hours, double dose before sleep.</description>
    <arm_group_label>Oral immediate-released morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years old or more;&#xD;
&#xD;
          2. ECOG PS ≤3 ;&#xD;
&#xD;
          3. Opioid tolerance not moderate pain patients (4≤ NRS ≤6 on 11 points, 0 no pain, 10&#xD;
             most pain);&#xD;
&#xD;
          4. No taking strong opioids for the last 30 days;&#xD;
&#xD;
          5. Estimated life expectancy of at least 3 months;&#xD;
&#xD;
          6. Ability to communicate effectively with the study personnel about the nature of their&#xD;
             pain;&#xD;
&#xD;
          7. Ability to complete a diary;&#xD;
&#xD;
          8. Cancer pain is expected to be relatively stable and last for more than 48 hours;&#xD;
&#xD;
          9. The patient understands the research process, agrees to participate in the trial,&#xD;
             cooperates with the treatment and visit plan, and signs an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy to any ingredient in both fentanyl and morphine;&#xD;
&#xD;
          2. No cancer associated pain or the pain of unknown cause, such as osteoarthritis pain,&#xD;
             acute abdominal pain;&#xD;
&#xD;
          3. Primary tumors or metastases in the brain;&#xD;
&#xD;
          4. An active skin disease that precluded application of the transdermal system;&#xD;
&#xD;
          5. Anti-cancer therapy (radiotherapy, chemotherapy, targeted therapy, etc.) is used&#xD;
             during the study period, and the treatment has an impact on the analgesic effect or&#xD;
             adverse reactions of analgesic drugs;&#xD;
&#xD;
          6. No bowel movement within 3 days before the screening period;&#xD;
&#xD;
          7. The patient has contraindications to the use of opioids: such as respiratory&#xD;
             depression; head damage; paralytic intestinal obstruction; acute abdomen; chronic&#xD;
             obstructive airway disease; pulmonary heart disease; chronic bronchial asthma;&#xD;
             hypercapnia;&#xD;
&#xD;
          8. Used monoamine oxidase inhibitor within 1 week before randomization;&#xD;
&#xD;
          9. Any abnormal laboratory test results with obvious clinical significance, such as&#xD;
             creatinine value ≥ 2 times the high limit of the normal value or ALT or AST ≥ 2.5&#xD;
             times the high limit of the normal value (for patients with liver metastases can be&#xD;
             relaxed to ≥ 5 times the high limit of the normal value) ;&#xD;
&#xD;
         10. Patients with a history of drug abuse;&#xD;
&#xD;
         11. Patients with mental illness or cognitive impairment;&#xD;
&#xD;
         12. Pregnant or lactating women; subjects who have a pregnancy plan within 1 month after&#xD;
             the test (including male subjects);&#xD;
&#xD;
         13. Participate in the drug trial (including the trial drug) within 3 months before the&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

